tailieunhanh - Báo cáo y học: "Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. | Available online http content 11 5 R142 Research article Preclinical characterization of DEKAVIL F8-IL10 a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis Kathrin Schwager1 Manuela Kaspar1 Frank Bootz1 2 Roberto Marcolongo3 Erberto Paresce4 Dario Neri2 and Eveline Trachsel1 Open Access 1Philochem AG c o ETH Zurich Institute of Pharmaceutical Sciences Wolfgang-Pauli-Strasse 1 0 HCI E520 CH-8093 Zurich Switzerland institute of Pharmaceutical Sciences ETH Zurich Wolfgang-Pauli-Strasse 10 CH-8093 Zurich Switzerland 3Centro Interdipartimentale Studio Biochimico-Clinico Patologie Osteoarticolari Via Doninzetti 7 University of Siena 53100 Siena Italy 4Department of Rheumatology Instituto Ortopedico Gaetano Pini via Pini 9 201 22 Milan Italy Corresponding author Dario Neri Received 9 Mar 2009 Revisions requested 15 Apr 2009 Revisions received 4 Sep 2009 Accepted 25 Sep 2009 Published 25 Sep 2009 Arthritis Research Therapy 2009 11 R142 doi 86 ar2814 This article is online at http content 11 5 R142 2009 Schwager et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction In this article we present a comparative immunohistochemical evaluation of four clinical-stage antibodies L19 F16 G11 and F8 directed against splice isoforms of fibronectin and of tenascin-C for their ability to stain synovial tissue alterations in rheumatoid arthritis patients. Furthermore we have evaluated the therapeutic potential of the most promising antibody F8 fused to the anti-inflammatory cytokine interleukin IL 10. Methods F8-IL10 was produced and purified to homogeneity in CHO cells and shown to comprise biological